ENvue Medical Stock Declines as 1-for-12 Reverse Split Takes Effect

Shares of ENvue Medical (Nasdaq: FEED) declined in morning trading on Tuesday after the company's previously announced 1-for-12 reverse stock split became effective. The stock, which began trading on a split-adjusted basis at the market open, fell as much as 1.5% amid wider market weakness.

Share Consolidation Details

ENvue Medical, a commercial-stage medical technology company, first announced the reverse split on August 28, 2026, with an effective date of September 1. The action consolidated every twelve pre-split shares into one new share, reducing the number of outstanding common shares from approximately 11.1 million to roughly 924,000.

While the stock continues to trade under the ticker symbol FEED on the Nasdaq Capital Market, it has been assigned a new CUSIP number. The company stated the move does not impact any stockholder’s percentage ownership, aside from the cash settlement of fractional shares. On a split-adjusted basis, the stock opened at $4.42 before trading down to $4.14.

Ad

Investor Concerns and Market Context

Reverse stock splits are often met with caution by investors, particularly in the micro-cap sector. The action for ENvue follows the company securing a sizable equity financing facility in August, which carries a risk of future share dilution for existing investors. This overhang, combined with the technical pressure of the split, contributed to the negative sentiment.

The decline also occurred within a challenging macroeconomic environment. Broader U.S. markets fell on Tuesday, driven by concerns over inflation, rising oil prices, and surging bond yields. The tech-heavy Nasdaq Composite was among the day's weakest-performing major indexes, creating significant headwinds for its smaller constituents like ENvue Medical.